S&P Futures
3,666.50 +12.25 (+0.34%) Dow Futures
29,353.00 +68.00 (+0.23%) Nasdaq Futures
11,260.75 +32.50 (+0.29%) Russell 2000 Futures
1,687.90 +5.80 (+0.34%) Crude Oil
81.56 +0.33 (+0.41%) Gold
1,671.60 +3.00 (+0.18%)
Opsens Inc. (OPSSF)
Chart Events
Performance Outlook
| Previous Close | 1.9000 |
| Open | 1.9050 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.8736 - 1.9100 |
| 52 Week Range | 1.2000 - 2.9900 |
| Volume | |
| Avg. Volume | 30,260 |
| Market Cap | 211.126M |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0460 |
| Earnings Date | Nov 21, 2022 - Nov 25, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for OPSSF
Related Research
- OPSENS INCDaily – Vickers Top Buyers & Sellers for 05/09/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat5 months agoArgus Research
- CNW Group
OPSENS ANNOUNCES FIRST SAVVYWIRE PROCEDURE IN THE UNITED STATES BY DR. PHILIPPE GENEREUX OF MORRISTOWN MEDICAL CENTER
OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that Dr. Philippe Genereux, Director of the Structural Heart Program at Morristown Medical Center in New Jersey, and his team, performed the first use of SavvyWire in a transcatheter aortic valve replacement (TAVR) procedure in the United States.
- CNW Group
OPSENS ANNOUNCES FDA CLEARANCE FOR THE SAVVYWIRE™ FOR USE IN TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) PROCEDURES
OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that it has received 510(k) regulatory clearance from the U.S. Food & Drug Administration ("FDA") for the SavvyWire™ ("SavvyWire"), its new guidewire for transcatheter aortic valve replacement procedures, or TAVR.
- CNW Group
OpSens to Participate in the Transcatheter Cardiovascular Therapeutics Conference (TCT) in Boston September 16-19, 2022
OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that it will present its latest innovations and sponsor a scientific program at Transcatheter Cardiovascular Therapeutics (TCT) September 16-19, 2022, held at the Boston Convention and Exhibition Center in Boston, MA. The TCT is an annual scientific symposium of the Cardiovascular Research Found
